Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers
- 15 April 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 99 (8), 2845-2850
- https://doi.org/10.1182/blood.v99.8.2845
Abstract
Read the full review for this F1000Prime recommended article: Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.Keywords
This publication has 27 references indexed in Scilit:
- Impaired activation of murine platelets lacking Gαi2Journal of Clinical Investigation, 2001
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsJournal of Clinical Investigation, 2001
- Human Small Cell Lung Carcinoma and Carcinoid Tumor Regulate Dendritic Cell Maturation and FunctionLaboratory Investigation, 2001
- Langerhans cell migrationClinical and Experimental Dermatology, 2000
- REVIEWCytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilizationBritish Journal of Dermatology, 2000
- Differential Regulation of Epidermal and Dermal Dendritic Cells by IL-12 and Flt3 LigandJournal of Investigative Dermatology, 1999
- Nitric Oxide Inhibits the Proliferation of T-Helper 1 and 2 Lymphocytes without Reduction in Cytokine SecretionCellular Immunology, 1999
- Antigen processing for amateurs and professionalsTrends in Cell Biology, 1998
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.The Journal of Experimental Medicine, 1996
- Dominance and Crypticity of T Cell Antigenic DeterminantsAnnual Review of Immunology, 1993